March 3, 2014
Bookmark and Share  
 
                 
  HCV
»
»
»
»
»



Follow us on
Twitter

HCVAdvocate


Join us on Facebook
Hcvadvocate Hcsp

 

Alan Franciscus

 

Greetings:

February was an incredible month in HCV news. First and foremost Gilead filed for marketing approval of the first interferon- and ribavirin-free therapy for treatment of HCV genotype 1. As well AbbVie completed their large Phase 3 studies and reported the results that are summarized in the current issue. AbbVie is also expected to file for marketing approval by the FDA this year. Both combinations are expected to be approved towards the end of this year. In addition we launched The HCV Advocate Daily that compiles all the news about hepatitis C from the internet.

Sincerely,

Alan and the staff of HCV Advocate

---------------------------------------------------------------------------

Do you want to stay up to date on the latest news about hepatitis C? Visit our HCV Advocate Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.

---------------------------------------------------------------------------

1. HCV Advocate Newsletter: March 2014

In This Issue:

-----------------------------------

2.HCV Advocate Launches "The HCV Advocate Daily"

The HCV Advocate has launched a tool to keep our readers up to date on the latest information about HCV. 

HCV Advocate Daily picks up news articles, provides a brief description of the story and a link to the entire article.   We hope that you will take advantage of this exciting new feature. 

-----------------------------------

3. HBV Journal Review: March 1, 2014, Vol 11, no 3, by Christine Kukka

In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including:

  • Tenofovir More Potent Than Entecavir in Patients with High Viral Loads;
  • Antiviral Treatment After Liver Cancer Surgery Improves Survival Dramatically
  • The New "Normal" ALT Levels Are Better at Diagnosing Active Infections
  • Culturally-Adept Program Boosts HBV Screening Among Asian-Americans
  • Experts Explore Ways to Treat and Monitor HBeAg-Negative Patients
  • CDC Experts Estimates 6.5 New Hepatitis B Infections for Every One Reported
  • Sperm Washing Successfully Prevents Infection Transmittal During Conception
  • Tenofovir Effective in Patients with Drug Resistance, But Less So with Adefovir-Resistance
  • Hepatitis B Vaccination Still Protects Even When Antibodies Decline

-----------------------------------

4. HCV Advocate News & Pipeline Blog!
Be sure to check out the latest clinical trial postings (Updated February 12, 2014) at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.

-----------------------------------

5.Need Help?!
Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.

———————————————


 

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 
  HBV
»
»
»

Follow us on Twitter
HBVAdvocate